NIH悬赏10万美元，寻求单细胞分析解决方案
2014-08-18 诸平 科学网博客
细胞是生物体结构和生命活动的基本单元。在单个细胞水平上进行研究，可以获得反映细胞生理状态和过程的更准确、更全面的信息，还可以使人们能更好地了解细胞群体中某些特殊的细胞功能，更深入地认识细胞个体差异、细胞间相互作用和信息传递以及神经递质、药物或毒物刺激的生理影响等更深层次的信息。因此，单细胞分析技术的研究与发展具有重要意义，已成为分析科学中的一个新兴的前沿领域。NIH悬赏10万美元，寻求单细胞分
细胞是生物体结构和生命活动的基本单元。在单个细胞水平上进行研究，可以获得反映细胞生理状态和过程的更准确、更全面的信息，还可以使人们能更好地了解细胞群体中某些特殊的细胞功能，更深入地认识细胞个体差异、细胞间相互作用和信息传递以及神经递质、药物或毒物刺激的生理影响等更深层次的信息。因此，单细胞分析技术的研究与发展具有重要意义，已成为分析科学中的一个新兴的前沿领域。NIH悬赏10万美元，寻求单细胞分析解决方案，起止日期为2014年8月15日到2014年12月15日，具体要求摘录如下：
原文链接点这里
AWARD: $100,000 USD | DEADLINE: 12/15/14 | ACTIVE SOLVERS: 25 | POSTED: 8/15/14
Many biological experiments are performed under the assumption that all cells of a particular “type” are identical. However, recent data suggest that individual cells within a single population may differ quite significantly and these differences can drive the health and function of the entire cell population. Single cell analysis comprises a broad field that covers advanced optical, electrochemical, mass spectrometry instrumentation, and sensor technology, as well as separation and sequencing techniques. Although the approaches currently in use can offer snapshots of single cells, the methods are often not amenable to longitudinal studies that monitor changes in individual cells in situ.
The NIH Single Cell Analysis Program (SCAP) is searching for novel methods for analyzing dynamic states of individual cells that can serve as the basis for predicting alterations in cell behavior and function over time. The ultimate goal is to develop new tools and methods that allow time-dependent measurements at the single cell level in a complex tissue environment to assess functional changes, provide information on the health status of a given cell, and help guide diagnosis and therapeutic treatments related to human disease states. Technological breakthroughs in this arena could allow researchers and physicians to identify rare cells in a mixed population such as individual cells that can transform and become cancerous; cells that are latently infected with a pathogenic virus; or cells that develop resistance to drugs over time. This challenge is structured in 2 phases: Phase 1 is a Theoretical Challenge and Phase 2, a Reduction to Practice Challenge. Phase 1 may award up to 6 prizes from a total prize award pool of $100,000 for the theoretical portion of the competition.
In addition to the direct monetary awards, the prize winners and selected runners-up will be recognized by the NIH Common Fund Single Cell Analysis Program and invited to attend The 3rd Annual Single Cell Analysis Investigators Meeting in Rockville, Maryland, USA on April 20, 2015. In addition to the public announcement, this opportunity may include paid travel and accommodations to the event and potential participation as an invited speaker at the discretion of the NIH.
Prize winners and selected runners-up with a qualifying score in Phase 1 will be invited to participate in Phase 2, which is a Reduction to Practice challenge to provide proof of concept data related to their Phase 1 entries. Phase 2 may award up to 2 winning solutions from a total pool of $400,000.
Phase 1 (Theoretical) Challenge requires only a written proposal.
Phase 2 (Reduction to Practice) Challenge will require documentation of Phase 1 implementation including the submission of data.
-------------------------------------
Source: InnoCentive Challenge ID: 9933618
Challenge Overview
Single cell analysis is a rapidly evolving field that encompasses many disciplines. For example, recent advances in single cell RNA and DNA sequencing technologies have showed great promise, but researchers must still be able to differentiate between biological variation and technical noise in the context of dynamic cellular states. The NIH Single Cell Analysis Program (SCAP) seeks novel robust methods for analysis of individual cells that can serve as the basis for assessment of changing cell behavior and function over time either as a result of natural state changes or when perturbed (e.g. by a drug, biological stimulus, infectious agent, pathological lesion, or mechanical forces). The Solver must rationalize how the application of the proposed method will successfully allow for monitoring of meaningful state changes in a single cell across time to answer at least one impactful, biological or clinical question.
Submissions to the Phase 1 Challenge must be received by 11:59 PM (US Eastern Time) on December 15, 2014. Late submissions will not be considered.
Phase 1 is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon evaluation of the written proposal by a technical evaluation panel serving the Seeker. Individuals and teams invited to participate in Phase 2, Reduction to Practice, may add members, who meet the eligibility requirements, to help support or sponsor efforts in Phase 2.
To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a non-exclusive license to practice their solutions.
IMPORTANT ELIGIBILITY INFORMATION
This Challenge is being held under the America COMPETES Authority where awards may only be awarded to individuals (participating singly or in a team) who are citizens or permanent residents of the United States. Only U.S. citizens and permanent residents are eligible to win a prize for this Challenge. Foreign citizens can participate as a member of team but will not be eligible to win a prize; however, acknowledgement of their participation as part of a winning team will be recognized when results are announced. If you have a question about eligibility, please read the Challenge Specific Agreement Eligibility Rules section or use your Project Room to ask a question. Details on the specific eligibility criteria are listed in the Federal Register Notice (https://federalregister.gov/a/2014-18870).
ABOUT THE SEEKER
The Single Cell Analysis Program (SCAP) is funded by the National Institutes of Health (NIH) Common Fund. The Common Fund began a decade ago to support collaborative programs with participation by all NIH Institutes and Centers. These programs must also be transformative, catalytic, synergistic, and unique. The overall goal of SCAP is to accelerate the discovery, development, and translation of cross-cutting, innovative approaches to analyzing the heterogeneity of biologically relevant populations of cells in situ. Through various grant mechanisms, SCAP currently supports multiple research projects including transcriptional profiling of single cells (U01), and development of new tools and technologies for single cell analysis (R21 and R01) (http://commonfund.nih.gov/singlecell/grants).
The majority of current SCAP awardees are associated with academic institutions. This Challenge will strengthen and complement the existing SCAP grant portfolio by reaching out to a broader diverse population of innovators and solvers, including not only those who are from academic institutions, but also those who are from research and development communities in the private sector, and those who are outside biomedical disciplines. It is hoped that this Challenge will stimulate investment from both public and private sectors in single cell analysis research and product development, which will in turn lead to the development of more sensitive, more robust, and more cost-effective assay approaches, reagents, tools, and devices for basic research and clinical diagnosis.
AWARD: $100,000 USD | DEADLINE: 12/15/14 | ACTIVE SOLVERS: 25 | POSTED: 8/15/14
Many biological experiments are performed under the assumption that all cells of a particular “type” are identical. However, recent data suggest that individual cells within a single population may differ quite significantly and these differences can drive the health and function of the entire cell population. Single cell analysis comprises a broad field that covers advanced optical, electrochemical, mass spectrometry instrumentation, and sensor technology, as well as separation and sequencing techniques. Although the approaches currently in use can offer snapshots of single cells, the methods are often not amenable to longitudinal studies that monitor changes in individual cells in situ.
The NIH Single Cell Analysis Program (SCAP) is searching for novel methods for analyzing dynamic states of individual cells that can serve as the basis for predicting alterations in cell behavior and function over time. The ultimate goal is to develop new tools and methods that allow time-dependent measurements at the single cell level in a complex tissue environment to assess functional changes, provide information on the health status of a given cell, and help guide diagnosis and therapeutic treatments related to human disease states. Technological breakthroughs in this arena could allow researchers and physicians to identify rare cells in a mixed population such as individual cells that can transform and become cancerous; cells that are latently infected with a pathogenic virus; or cells that develop resistance to drugs over time. This challenge is structured in 2 phases: Phase 1 is a Theoretical Challenge and Phase 2, a Reduction to Practice Challenge. Phase 1 may award up to 6 prizes from a total prize award pool of $100,000 for the theoretical portion of the competition.
In addition to the direct monetary awards, the prize winners and selected runners-up will be recognized by the NIH Common Fund Single Cell Analysis Program and invited to attend The 3rd Annual Single Cell Analysis Investigators Meeting in Rockville, Maryland, USA on April 20, 2015. In addition to the public announcement, this opportunity may include paid travel and accommodations to the event and potential participation as an invited speaker at the discretion of the NIH.
Prize winners and selected runners-up with a qualifying score in Phase 1 will be invited to participate in Phase 2, which is a Reduction to Practice challenge to provide proof of concept data related to their Phase 1 entries. Phase 2 may award up to 2 winning solutions from a total pool of $400,000.
Phase 1 (Theoretical) Challenge requires only a written proposal.
Phase 2 (Reduction to Practice) Challenge will require documentation of Phase 1 implementation including the submission of data.
-------------------------------------
Source: InnoCentive Challenge ID: 9933618
Challenge Overview
Single cell analysis is a rapidly evolving field that encompasses many disciplines. For example, recent advances in single cell RNA and DNA sequencing technologies have showed great promise, but researchers must still be able to differentiate between biological variation and technical noise in the context of dynamic cellular states. The NIH Single Cell Analysis Program (SCAP) seeks novel robust methods for analysis of individual cells that can serve as the basis for assessment of changing cell behavior and function over time either as a result of natural state changes or when perturbed (e.g. by a drug, biological stimulus, infectious agent, pathological lesion, or mechanical forces). The Solver must rationalize how the application of the proposed method will successfully allow for monitoring of meaningful state changes in a single cell across time to answer at least one impactful, biological or clinical question.
Submissions to the Phase 1 Challenge must be received by 11:59 PM (US Eastern Time) on December 15, 2014. Late submissions will not be considered.
Phase 1 is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon evaluation of the written proposal by a technical evaluation panel serving the Seeker. Individuals and teams invited to participate in Phase 2, Reduction to Practice, may add members, who meet the eligibility requirements, to help support or sponsor efforts in Phase 2.
To receive an award, Solvers will not be required to transfer their exclusive IP rights to the Seeker. Instead, Solvers will grant to the Seeker a non-exclusive license to practice their solutions.
IMPORTANT ELIGIBILITY INFORMATION
This Challenge is being held under the America COMPETES Authority where awards may only be awarded to individuals (participating singly or in a team) who are citizens or permanent residents of the United States. Only U.S. citizens and permanent residents are eligible to win a prize for this Challenge. Foreign citizens can participate as a member of team but will not be eligible to win a prize; however, acknowledgement of their participation as part of a winning team will be recognized when results are announced. If you have a question about eligibility, please read the Challenge Specific Agreement Eligibility Rules section or use your Project Room to ask a question. Details on the specific eligibility criteria are listed in the Federal Register Notice (https://federalregister.gov/a/2014-18870).
ABOUT THE SEEKER
The Single Cell Analysis Program (SCAP) is funded by the National Institutes of Health (NIH) Common Fund. The Common Fund began a decade ago to support collaborative programs with participation by all NIH Institutes and Centers. These programs must also be transformative, catalytic, synergistic, and unique. The overall goal of SCAP is to accelerate the discovery, development, and translation of cross-cutting, innovative approaches to analyzing the heterogeneity of biologically relevant populations of cells in situ. Through various grant mechanisms, SCAP currently supports multiple research projects including transcriptional profiling of single cells (U01), and development of new tools and technologies for single cell analysis (R21 and R01) (http://commonfund.nih.gov/singlecell/grants).
The majority of current SCAP awardees are associated with academic institutions. This Challenge will strengthen and complement the existing SCAP grant portfolio by reaching out to a broader diverse population of innovators and solvers, including not only those who are from academic institutions, but also those who are from research and development communities in the private sector, and those who are outside biomedical disciplines. It is hoped that this Challenge will stimulate investment from both public and private sectors in single cell analysis research and product development, which will in turn lead to the development of more sensitive, more robust, and more cost-effective assay approaches, reagents, tools, and devices for basic research and clinical diagnosis.
版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
#解决方案#
80
#NIH#
93